Kimmell Cybersecurity Achieves CMMC Level 2 Certification for MSP and MSSP Services, Strengthening Cybersecurity for DoD Contractors
Kimmell Cybersecurity - MSP / MSSP meets DOD's stringent CMMC security requirements achieving CMMC Level 2 certification.
This certification is especially significant for Department of Defense (DoD) contractors handling Controlled Unclassified Information (CUI), as it ensures Kimmell Cybersecurity's managed services meet the same rigorous standards required of their clients under the NIST SP 800-171 Rev 2 framework.
'For DoD contractors navigating the complexities of CMMC compliance, this certification proves that our team practices exactly what we assess,' said Brett Kimmell, Managing Member at Kimmell Cybersecurity. 'We understand contractor's unique challenges and offer managed services that are not only compliant but tested to the highest federal standards.'
The independent third-party assessment verified that Kimmell Cybersecurity has implemented and maintains all security practices required for CMMC Level 2 certification—strengthening the company's position as a trusted cybersecurity partner for contractors building the future of U.S. defense.
With this milestone, DoD contractors and subcontractors can rely on Kimmell Cybersecurity for expert CMMC assessments, consulting, and Level 2-certified managed services that directly support compliance readiness.
To learn more email cmmc@kimmell.com or contact Erik Bennett 330-762-5143 or ebennett@kimmell.com.
About Kimmell Cybersecurity
Kimmell Cybersecurity is a leading CMMC C3PAO, delivering certified cybersecurity assessments, advisory, and fully managed services tailored to DoD manufacturers and contractors. With deep experience in defense compliance, Kimmell helps organizations secure their systems, safeguard CUI, and achieve CMMC certification with confidence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 hours ago
- Business Wire
Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense's premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation in support of warfighter health and readiness. Direct Access to DoD Decision-Makers and Researchers MHSRS provides direct access to organizations seeking military partnerships and connects companies with key funding organizations. Tivic's President of Biopharma and Chief Operating Officer, Michael Handley, met with key members of the Biomedical Advanced Research and Development Authority (BARDA), the Armed Forces Radiobiology Research Institute (AFRRI) and the Medical CBRN Defense Consortium (MCDC) to discuss potential pathways to deploy Entolimod as a military countermeasure. BARDA's mission is to develop medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. AFRRI's mission is to defend the Nation from nuclear and radiological threats through research, leadership, training, and education. The MCDC was formed in response to the US Government's expressed interest to engage and fund advanced development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. 'It was an honor to contribute to the vital conversations that were focused generally on radiation medical countermeasures, and specifically on our lead clinical product candidate, Entolimod, which has the potential to protect the warfighter in the instance that they are exposed to radiation,' said Handley. Representatives from Tivic joined global thought leaders, military leaders and researchers to share insights, explore collaborative opportunities, and present ongoing research intended to improve health outcomes for warfighters exposed to radiation in the field. About MHSRS MHSRS serves as a dynamic platform for the exchange of research findings across multiple disciplines, including combat casualty care, medical countermeasures, infectious disease, and mental health. The symposium fosters collaboration among business leaders, scientists, clinicians, and policymakers, ensuring innovations reach those who serve as quickly and effectively as possible. About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities, as well as interactions with governmental agencies, such as BARDA, the AFRRI and the MCDC; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Tom's Guide
10 hours ago
- Tom's Guide
I love my Ninja Creami, but Cuisinart's affordable handheld alternative just blew me away
As soon as I discovered Cuisinart's Fast Freeze ice cream maker, I've been dying to try it. I'm obsessed with my Ninja Creami, but this Cuisinart dupe is only $119 / £99, and takes up a lot less counter space. The Fast Freeze is called the Freeze Wand in the U.K., and I think that's a much better name. There's nothing fast about it: you need to freeze your mixture overnight, just like you do with the Ninja Creami. However, it does perform a lot like a magic wand, turning your frozen mixtures into tasty desserts in minutes. Best of all, this handheld ice cream maker comes with much smaller containers, which is a blessing for my over-filled freezer and penchant for single-serve frozen treats. But after my first time using the Fast Freeze, I'm more than a little shocked by how easily it sliced through my frozen chocolate milk to make tasty, zero-effort ice cream. Here's how my first impressions went. For $119, the FastFreeze comes with three half-pint containers for pre-prepping your ingredients, and has five churning settings. Different name, same great idea. The Freeze Wand also has five settings, three containers, and costs under £100 for U.K. shoppers. The FastFreeze has a spinning blade that slices through your frozen mix as you push the top of the wand down. It works a bit like an AeroPress, using your manual pressure to plunge down the blending compartment. I pre-froze three mixtures for my test: a tropical fruit just to make a slushie, a strawberry yogurt to make fro-yo, and a low-fat chocolate milk to make a healthier alternative to gelato. For my first impressions, I decided to start with my chocolate milk mixture, which couldn't have been easier to prepare. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. You can choose between five settings on the blending wand before you churn your ice cream mix. You can twist the dial to switch between these settings, then press the 'Play' button, and gently press down the wand mechanism to process your mix. Given how much noise my Ninja Creami kicks up when it's churning ice cream, I was expecting this to be a lot more noisy, and scary, than it really was. I thought I must've done something wrong when my wand's light turned red, but it turns out that just means you've finished blending. It took around a minute and made only a small fraction of the noise the Ninja Creami makes! I was left with a cup of fully-churned ice cream. It looked a little grainy at first, which is largely on account of the low fat content of the milk as opposed to a fault of the FastFreeze, and once I gave it a good stir it came together in a thick, scoopable texture. The half-pint cup (you can't fill to the top, so it doesn't leave you with half a pint of ice cream) was ideal for a single serving. But because the ice cream maker comes with three cups, you might find it's not ideal for catering to a crowd. I can't see an option to buy more cups online, which feels like an oversight from Cuisinart, but hopefully they'll release some soon in order to allow customers to prep plenty of treats far in advance. I'll be prepping a proper gelato recipe from Cuisinart's own recipe book to really put this ice cream maker through its paces, but like I said, the low-fat chocolate milk did result in a more frosty consistency that needed some mixing to form a scoopable texture. However, once I served a scoop to my partner, he assumed I'd made it in the Ninja Creami, which felt like a real win considering how much more expensive the Creami is than the FastFreeze. Aside from a tiny bit of crystallization around the exterior of the cup, the ice cream was super smooth and didn't have any lumps. It was super tasty, so from my first impression there's no obvious trade-offs if you opt for the Cuisinart over a Ninja machine. If anything, the reduced noise and size requirements could make it a much more tempting option for the average user. I'll be writing my complete review, as well as a side-by-side comparison with my Ninja Creami, in the weeks to come. But if first impressions are anything to go by, the FastFreeze could be a real game-changer. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Yahoo
a day ago
- Yahoo
BigBear.ai Holdings Shares Plunge. Is This a Buying Opportunity or a Red Flag?
Key Points badly missed revenue expectations in Q2. The company now expects to report its lowest-ever yearly revenue as a public company. It does not show the characteristics of an AI software company. 10 stocks we like better than › Share prices of (NYSE: BBAI) plunged earlier this week after the analytics and systems integrator badly missed revenue and earnings expectations when it reported its second-quarter results. However, the stock is still trading up more than 300% over the past year, as of this writing. The shares initially staged a big rally in early February after the company announced a contract win with the Department of Defense's (DoD) Chief Digital and Artificial Intelligence Office to design a Virtual Anticipation Network (VANE) prototype. This platform will use artificial intelligence (AI) models to analyze news media coming from potential U.S. adversaries. After a pullback following this strong early-year run, the stock rallied again to start the summer. A combination of overall strong AI sentiment, along with a few notable announcements -- such as a new strategic partnership in the United Arab Emirates and its participation in Project Convergence-Capstone 5 (PC-C5) -- helped power the stock ahead. Let's take a closer look to see if the drop could be a buying opportunity, or if it's a warning to stay away. A big revenue miss for In Q2, badly missed revenue expectations, as revenue sank 18% year over year to $32.5 million. That missed the $40.6 million analyst consensus, as compiled by S&P Global Market Intelligence. The company blamed the miss on the federal government's efforts to reduce costs, saying that this disrupted contracts it has with the United States Army, which has been working to modernize its data architecture. Note, however, that this doesn't appear to have affected Palantir Technologies, which reported great results and recently signed a $10 billion, 10-year contract with the U.S. Army that consolidated 75 contracts into a single contract. said it "welcomes" this type of disruption, as it will lead to the Army using more software solutions to solve mission-critical problems. However, CEO Kevin McAleenan admitted that the company relies on too few large contracts and needs to broaden its customer base and the market it serves. How much of a true software company actually is, though, is questionable, as can be seen in its low gross margins. In the quarter, its gross margin fell to 25% from 27.8% a year ago. Those are just not software or AI gross margins. Because the company's engineers and data scientists must co-locate and be on-premises for many of its government projects, it has structurally low gross margins. Gross margins are important, as the higher they are, the easier it is to turn revenue into profits. In comparison, Palantir had a gross margin of nearly 81% in Q2. On the profitability front, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was a loss of $8.7 million, compared to a loss of $3.7 million a year ago. The decline came from lower revenue, reduced gross margin, and higher research and development expenses. The company continued to burn cash in the quarter, but it took advantage of its high stock price to sell shares and solidify its balance sheet. It generated cash flow from operations of negative $3.9 million in the quarter and negative $7.1 million in the first half. However, after raising $293.4 million in proceeds from at-the-market (ATM) stock sales, it ended the quarter with $390.8 million in cash and equivalents and $103.1 million in debt. Looking ahead, reduced its full-year revenue forecast to be between $125 million and $140 million, down from a prior outlook of $160 million to $180 million. That would be a decline from the $158.2 million in revenue the company saw in 2024. Should investors buy the dip or stay away? is simply not a software company riding the AI wave. It doesn't have the gross margins or predictable revenue stream of a software-as-a-service (SaaS) company. It also hasn't seen a big revenue lift from AI. In fact, its revenue this year is set to come in at the lowest level ever since the stock debuted in December 2021 through a SPAC. While the stock has staged a big rally this year, its share count is also up nearly 50% in the past year. That's massive dilution. The company has done nothing to deserve the big rally it's seen over the past year, and I think the sell-off in the stock was actually pretty tame given its results and guidance. While some investors may want to hope that can turn into the next Palantir, that is just highly unlikely. I think a lot more downside could be in store, and as such, I'd stay far away. Do the experts think is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,062% vs. just 185% for the S&P — that is beating the market by 877.34%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies and S&P Global. The Motley Fool has a disclosure policy. Holdings Shares Plunge. Is This a Buying Opportunity or a Red Flag? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
